Diseases
The World Organization for Animal Health (WOAH) has formally recognized Brazil as a country free of foot-and-mouth disease without vaccination, marking a major achievement for the country's livestock sector. This milestone was granted during the 92nd General Session of the WOAH World Assembly of Delegates, and it applies
Diseases
Recent research on non-alcoholic fatty liver disease (NAFLD) has demonstrated the efficacy of statins in reducing liver enzymes, improving histological features, and attenuating disease progression in patients with NAFLD. Statins target key pathogenic pathways in NAFLD, including the inhibition of sterol regulatory element-binding proteins (SREBPs), activation of peroxisome proliferator-activated receptor-alpha
Diseases
A rising concern in the UK is the incidence of fatty liver disease, also known as hepatic steatosis, which affects up to 20% of adults. This condition can lead to inflammation, fibrosis, cirrhosis, and even liver failure or cancer. However, a hepatologist and gastroenterologist, Dr. Saurabh Sethi, has suggested that
Diseases
A study published in the Russian Journal of Genetics has shed light on the genetic factors influencing the development and progression of non-alcoholic fatty liver disease (NAFLD). Researchers from the Russian Academy of Sciences studied the relationship between polymorphism markers of the PNPLA3, UCP2, and HFE genes and metabolic changes
Diseases
Research from Fujian Medical University in People's Republic of China suggests that cheese consumption may have a negative association with the risk of non-alcoholic fatty liver disease (NAFLD). The study, published in Food Science & Nutrition, employed a two-sample Mendelian randomization approach to explore the causal relationship between
Diseases
Researchers in Liaoning, People's Republic of China have conducted a study on the effectiveness of a Deep Neural Network (DNN)-based ophthalmic disease diagnosis framework in facilitating personalized medication treatment plans. The study employed a prospective, single-center, randomized controlled clinical trial design to treat 500 patients with common
Diseases
Research conducted by Rutgers University New Jersey Medical School has revealed the vital importance of iron in human health, particularly in relation to gut microbiota dysbiosis and disease. The study, supported by the U.S. Department of Health & Human Services and the National Institutes of Health, emphasizes that iron
Antiarthritic agents
Glenohumeral osteoarthritis (GHOA) is a prevalent and costly problem among the aging population, with a significant burden on healthcare systems globally. Despite its impact, the underlying pathobiology and pathomechanics of the disease remain poorly understood, and treatment options are limited. A recent study, conducted in collaboration with the Arthritis Foundation
Diseases
The National Institute for Health and Care Excellence (Nice) has reaffirmed its decision to reject two Alzheimer's treatments, donanemab and lecanemab, citing their high cost and modest benefits for patients. The treatments, developed by Lilly and Eisai, respectively, target a known cause of Alzheimer's disease, amyloid,
Diseases
In a surprise twist, researchers have discovered that a protein from Helicobacter pylori, a bacterium commonly associated with stomach ulcers, can block the toxic buildup of amyloid-beta and tau proteins, which are central to Alzheimer's disease. This finding could potentially lead to a new strategy for treating the
Diseases
Polycystic kidney disease, a genetic disorder that causes numerous fluid-filled cysts in the kidneys, is anticipated to see a significant rise in its market size, driven by the increasing prevalence and awareness of the disease. The market is expected to grow with a substantial CAGR during the study period (2020-2034)
Diseases
The celiac disease treatment market is rapidly expanding, driven by increasing awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players. According to a recent report by DelveInsight, the US held the largest share of the celiac disease drugs market in 2023, accounting for approximately 70% of the total market
